Patient Corner

Anatomical Illustrations

More

Last reference updates

  • Aug 18, 2017 - FDA Drug Updates

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

Besponsa (inotuzumab ozogamicin) is new targeted therapy for acute lymphoblastic leukemia

Read more
  • Aug 18, 2017 - MedWatch Drug Updates

Class I recall of Zenith Alpha Thoracic Endovascular Graft by Cook Medical – thrombus may form inside the device

Class I recall of Zenith Alpha Thoracic Endovascular Graft by Cook Medical because of formation of thrombus inside the device after implantation

Read more
  • Aug 18, 2017 - MedWatch Drug Updates

Recall of lorazepam oral concentrate, USP 2mg/mL - defect in the dropper markings

Recall of lorazepam oral concentrate, USP 2mg/mL because of misprinted dosing droppers supplied with the product

Read more
  • Aug 14, 2017 - MedWatch Drug Updates

FDA Alert: Lack of sterility assurance for sterile drug products from Vital Rx, dba Atlantic Pharmacy and Compounding

Administration of a non-sterile product intended to be sterile may result in serious and potentially life threatening infections or death.

Read more
  • Aug 14, 2017 - MedWatch Drug Updates

FDA safety alert: Potential complication associated with liquid-filled intragastric balloon systems

FDA update to health care providers on potential complication associated with liquid-filled intragastric balloon systems used to treat obesity.

Read more
  • Aug 14, 2017 - MedWatch Drug Updates

Recall of all liquid products manufactured by PharmaTech: Risk of product contamination

Recall of all liquid products manufactured by PharmaTech and distributed by Leader Brand, Major Pharmaceuticals, and Rugby Laboratories due to risk of product contamination.

Read more
  • Aug 14, 2017 - MedWatch Drug Updates

Recall of pravastatin sodium tablets by International Laboratories: Mislabeled and contained different drug

Recall of pravastatin sodium tablets USP 40 mg by International Laboratories as it was mislabelled and contained bupropion hydrochloride XL 300 mg tablets.

Read more
  • Aug 2, 2017 - FDA Drug Updates

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

FDA approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML)

Read more
  • Jul 24, 2017 - MedWatch Drug Updates

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

Penumbra recalled 3D Revascularization device due to separation of delivery wire which may enter into patient’s brain bloodstream and cause serious adverse events.

Read more
  • Aug 9, 2017 - MedWatch Drug Updates

FDA advise not to use any liquid product manufactured by PharmaTech due to possible contamination

FDA urges do not use any liquid product manufactured by PharmaTech due to possible contamination with Burkholderia cepacia.

Read more